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Atopic dermatitis is known to be common among children, but there are few studies examin-
ing the epidemiology across the life course. In particular, there is a paucity of data on atopic
dermatitis among older adults.
Objective
To evaluate participant characteristics, patterns of disease activity and severity, and calen-
dar trends in older adult atopic dermatitis in comparison to other age groups in a large popu-
lation-based cohort.
Methods
This was a cohort study of 9,154,936 individuals aged 0–99 years registered in The Health
Improvement Network, a database comprised of electronic health records from general
practices in the United Kingdom between 1994 and 2013. Atopic dermatitis was defined by
a previously validated algorithm using a combination of at least one recorded atopic dermati-
tis diagnostic code in primary care and two atopic dermatitis therapies recorded on separate
days. Cross-sectional analyses of disease prevalence were conducted at each age. Logistic
mixed effect regression models were used to identify predictors of prevalent disease over
time among children (0–17 years), adults (18–74 years), and older adults (75–99 years).
Results
Physician-diagnosed atopic dermatitis was identified in 894,454 individuals with the follow-
ing proportions in each age group: 18.3% of children, 7.7% of adults, and 11.6% of older
adults. Additionally, atopic dermatitis prevalence increased across the 2-decade period
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(beta from linear regression test for trend in the change in proportion per year = 0.005, p =
0.044). In older adults, atopic dermatitis was 27% less common among females (adjusted
OR 0.73, 95% CI 0.70–0.76) and was more likely to be active (59.7%, 95% CI 59.5–59.9%)
and of higher severity (mean annual percentage with moderate and severe disease: 31.8%
and 3.0%, respectively) than in other age groups.
Conclusion
In a large population-based cohort, the prevalence of physician-diagnosed atopic dermatitis
has increased throughout adulthood and was most common among males age 75 years
and above. Compared to children ages 0–17 and adults ages 18–74, older adult atopic der-
matitis was more active and severe. Because the prevalence of atopic dermatitis among
older adults has increased over time, additional characterization of disease triggers and
mechanisms and targeted treatment recommendations are needed for this population.
Introduction
Atopic dermatitis (also known as atopic eczema, or simply eczema) is a common inflammatory
condition that manifests as dry, severely itchy skin [1]. While much of the early literature on
this condition has focused on childhood disease, newer evidence suggests that atopic dermati-
tis is also common during adulthood [2, 3]. Older adults, in particular, have not been well-rep-
resented in epidemiologic studies of atopic dermatitis nor in clinical trials for novel treatments
[4].
Differences in both demographic characteristics and clinical manifestations of atopic der-
matitis have been identified between children and adults, demonstrating the importance of
studying atopic dermatitis past childhood [2, 5, 6]. In a recent study to identify the prevalence
of physician-diagnosed atopic dermatitis across the lifespan, we found unexpectedly high rates
of atopic dermatitis among older adults [3]. A small body of literature has described ‘senile’
atopic dermatitis, but there remains a gap in our understanding of the epidemiology of atopic
dermatitis in this population [6, 7]. Understanding disease trends among older adults is a pri-
ority because they comprise the most rapidly growing demographic group worldwide—by
2050, the population of adults over the age of 80 in the United States (US) is expected to triple
[8]. Additionally, older adults are often affected by other health conditions that may influence
atopic dermatitis treatment choice. These unique considerations underscore the importance of
studying the epidemiology and disease characteristics of atopic dermatitis in the older adult
population.
Our objective was to characterize the epidemiology of atopic dermatitis among older adults
as compared to other age groups in a large population-based sample. Specifically, we examined
the prevalence of atopic dermatitis by age and whether this changed over time, investigated the
association between patient characteristics and the age-specific prevalence of atopic dermatitis,
and identified patterns of disease activity and severity by age group.
Methods
Population
We conducted a longitudinal analysis using routinely collected primary care data from The
Health Improvement Network (THIN) cohort (Fig 1). THIN consists of anonymized elec-
tronic health records of patients registered with more than 500 participating general practices
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in the United Kingdom (UK), covering approximately 6% of the UK population, and has been
widely used for longitudinal analyses of chronic health conditions [9–13]. The data are valid
for many chronic conditions, and the population is generalizable to the larger UK population
in which general practitioners manage 97% of atopic dermatitis cases [10]. This study was
approved by the THIN SRC (Reference 14–083), considered exempt by the University of
Pennsylvania IRB, and not considered human subjects research by the UCSF IRB.
The analysis population included all patients between 0–99 years old who were registered at
participating practices in the UK during the follow-up window. The start of follow-up began
from the latest of the following dates: date the patient registered with the practice, date the
practice met data quality control standards, or the start of the cohort (January 1, 1994). The
follow-up period ended at the earliest of the following dates: recorded death date, last visit with
the practice, end of registration with the practice, or the end of available follow-up data (Janu-
ary 15, 2013).
Variables
Atopic dermatitis diagnosis was determined by a combination of at least one recorded atopic
dermatitis diagnostic code in primary care (THIN, using Read codes) and two atopic dermati-
tis therapies recorded on separate days, as previously validated [9]. The positive predictive
value of this algorithm for identifying physician-confirmed atopic dermatitis among all adults
over age 18 was 82% (95% CI 73–89%). Among the subset of adults in this sample over age 75,
the positive predictive value was 85% (95% CI 55–98%). Atopic dermatitis therapy categories
included the following: emollients, topical corticosteroids, topical calcineurin inhibitors
(tacrolimus and pimecrolimus), oral glucocorticoids, azathioprine, ciclosporin, methotrexate,
and mycophenolate mofetil. The date of diagnosis was set as the date of the latest recorded
Fig 1. Graphical depiction of study design. Participants were followed for up to 20 years at differing ages; if
individuals met atopic dermatitis diagnosis criteria, they were assessed for active disease during each subsequent year
of follow-up.
https://doi.org/10.1371/journal.pone.0258219.g001
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component (i.e. atopic dermatitis diagnostic code or second record for atopic dermatitis ther-
apy) in the algorithm. Therapies were selected based on British National Formulary codes and
individually reviewed to ensure relevance (i.e. topical rather than optical steroids) (S1 Table).
Prevalent atopic dermatitis was defined on a yearly basis as any additional atopic dermatitis
medical code from a physician visit or prescription for an atopic dermatitis treatment during a
year of follow-up after a patient met the atopic dermatitis definition. The year in which a par-
ticipant ended their follow-up was used as a proxy to assess for the association between calen-
dar time and atopic dermatitis. Socioeconomic status was measured using the Townsend
Deprivation Score, an area-level measure encompassing unemployment and household
crowding rates as well as home and car ownership, based on Census data for groups of about
150 households [14]. The score was reported in quintiles with higher quintiles reflecting higher
amounts of deprivation, or lower socioeconomic status. Urban/rural classification, or setting,
was based on the Office of National Statistics guidelines [15]. Demographic data were recorded
at the time of registration.
Analyses
Age-specific prevalence of atopic dermatitis was calculated in a series of cross-sectional analy-
ses by dividing the number of patients who met the validated atopic dermatitis definition and
had additional atopic dermatitis codes in any given year by the total number of patients being
followed at the same age. Local polynomial smoothed plots were generated from cross-sec-
tional calculations at each age by participant characteristics and by calendar period. Based on
the demographic trends identified in these plots, we grouped the population into three age cat-
egories for stratified regression analyses: children (ages 0–17), adults (ages 18–74), and older
adults (ages 75–99). Within each group, we quantified the association of age, calendar period,
area of residence (urban/rural), sex, and Townsend Deprivation Score with the odds of preva-
lent atopic dermatitis during any given year using multivariable mixed effects logistic regres-
sion models. These variables were chosen a priori and were all included in the final models,
regardless of significance level in univariate analyses.
We also examined atopic dermatitis activity and severity by age group. Disease activity was
determined by dividing the number of years in which an individual had an additional diagno-
sis or treatment code for atopic dermatitis by the total number of years of follow-up for that
individual. Disease severity was designated as mild, moderate, or severe based on treatment
and referral patterns in a time-updated progressive manner. These designations were based on
National Institute for Health and Care Excellence (NICE) treatment recommendations and
have been used in prior studies [16, 17]. At any given point during follow-up, atopic dermatitis
patients belonged to one of three severity categories: mild, moderate, or severe. By default, all
individuals with atopic dermatitis were classified as having mild disease. They were classified
as having moderate atopic dermatitis from the earliest of: 1) second potent topical steroid
treatment within a year, or 2) first calcineurin inhibitor treatment (NICE recommends calci-
neurin inhibitors only as a second-line treatment for moderate-to-severe disease in the UK)
[18]. Individuals were classified as having severe atopic dermatitis from the earliest of: 1) first
systemic treatment for atopic dermatitis (i.e. a record of a prescription for cyclosporine, azathi-
oprine, mycophenolate or methotrexate), or 2) first phototherapy code, or 3) first referral to
secondary care for atopic dermatitis. Of note, only 3% of atopic dermatitis patients are man-
aged by dermatologists in the UK, and referral to tertiary care is recommended for severe dis-
ease [19, 20]. Oral glucocorticoids were not included in the definition based on NICE
guidance and international standards [18, 21]. Participants could progress from mild, to mod-
erate, to severe disease but they did not necessarily have to progress in a stepwise order; they
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could be assigned directly to the severe atopic dermatitis category. However, participants were
not considered to progress to less severe categories of atopic dermatitis—once defined as mod-
erate, atopic dermatitis patients remained as such unless they developed severe atopic dermati-
tis; once defined as severe, atopic dermatitis patients remained as such.
Additional analyses
We performed additional analyses to examine the stability of our results to potential biases.
First, to examine the possibility of bias due to short durations of follow-up, we repeated the cal-
culation of disease activity after restricting to a subset of individuals with at least 2 years of fol-
low-up. Second, we examined the possibility of ascertainment bias, given that young and old
individuals are more likely to seek care and therefore may be more likely to receive atopic der-
matitis diagnoses. In a random 1% sample of the population (N = 91,549), we recreated the
graph depicting prevalence of disease by age after restricting the sample to individuals with at
least one physician’s visit at that age.
Finally, we recreated the same graph in a validation analysis using data from the 2005–2006
US National Health and Nutrition Examination Survey (NHANES). The NHANES 2005–2006
cohort was selected from among other waves of NHANES because it contained several ques-
tions specifically pertaining to atopic dermatitis and was administered to individuals of all ages
(0–85+), demonstrating the greatest overlap in age with our sample in THIN. We combined
questions as others have done [22] and examined three potential definitions related to atopic
dermatitis: 1) Answered ‘yes’ to “Ever had an itchy rash which was coming and going for at
least 6 months?” and “Itchy rash at any time in the last 12 months?” 2) Answered ‘yes’ to Defi-
nition 1 questions, and answered ‘yes’ to “Has this rash cleared up completely at any time dur-
ing the last 12 months?” and “Itchy rash at any time affecting: the folds of the elbows, behind
the knees, in front of the ankles, under the buttocks, or around the neck, ears, or eyes?” 3)
Answered ‘yes’ to Definition 1 questions, and answered ‘yes’ to “Doctor or health professional
ever told you that you had eczema?” An explanation for the measure of socioeconomic status
used in this validation analysis is included in S1 Methods.
Missing data
We examined patterns of missing data by age and atopic dermatitis status (S2 and S3 Tables).
For the primary analysis, we performed a complete case analysis. To explore the effect of miss-
ing data, we performed multiple imputation with iterative chained equations to impute miss-
ing covariate data in setting and Townsend Score. Given the large number of observations in
this dataset and the nature of repeated measures, we performed multiple imputation on a ran-
dom 1% sample of the population (N = 91,549). Ten imputed datasets were generated, and the
average results from repeated analyses were compared with complete case analysis in the same
random 1% sample. All statistical analyses were performed using Stata 16.1 (StataCorp).
Results
Participant characteristics
We identified 894,454 individuals who ever met the definition for atopic dermatitis among a
total population of 9,154,936. On average, a greater proportion of participants with atopic der-
matitis was female, resided in an urban setting, and had higher socioeconomic status com-
pared with non-atopic dermatitis patients (Table 1). Overall, 8.3% of participants were missing
covariate data on the Townsend Deprivation Score and 20.9% were missing data on urban/
rural setting. This proportion with missing data were similar between age group, though
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participants with missing data were less likely to have atopic dermatitis diagnoses (Table 1, S2
and S3 Tables).
Atopic dermatitis prevalence by participant characteristic
Annual atopic dermatitis prevalence ranged by age from 6.1–21.2% among children ages 0–17,
3.5–7.8% among adults ages 18–74, and 7.0–9.3% among older adults ages 75–99. In mixed
models, we found that the prevalence of atopic dermatitis increased with age among older
adults (Adjusted Odds Ratio (AOR) 1.06, 95% CI 1.06–1.06, i.e. a 6% increase in odds per year
of age), whereas the prevalence decreased by 14% annually among children (Fig 2 and
Table 2).
Atopic dermatitis was less common among female older adults: they had about three-
fourths the odds of prevalent disease as their male counterparts (AOR 0.73, 95% CI 0.70–0.76).
In contrast, female adults ages 18–74 years had a nearly three times higher odds of atopic der-
matitis (AOR 2.72, 95% CI 2.68–2.76) compared to males in their age group. The odds of
atopic dermatitis were 9–24% higher in urban as compared to rural settings across the age cat-
egories. Socioeconomic trends differed only among children: the odds of atopic dermatitis
were smaller in more deprived groups among those 0–17 years, though in adults ages 18–74
years and 75–99 years there was no difference between the most deprived and least deprived
groups, though the intermediately deprived groups (Townsend 2–4) still had higher odds of
atopic dermatitis compared to the least deprived group (Table 2). Analyses in a random 1%
sample of the population showed similar results when performing complete case analysis com-
pared to multiple imputation (S4 Table).
A sensitivity analysis restricted to individuals with at least one physician’s visit during that
year did not show evidence of ascertainment bias; although the prevalence was slightly higher
at all ages, the shape of the curve was similar (S1 Fig).
Table 1. Participant characteristics.
Characteristic All (N = 9,154,936) Atopic dermatitis (N = 894,454) Non-atopic dermatitis (N = 8,260,482)
Age at start of follow-up, No. (%)
Children (0–17 years) 1,400,354 255,622 (18.3) 1,144,732 (81.7)
Adults (18–74 years) 6,731,678 520,402 (7.7) 6,211,276 (92.3)
Older adults (75–99 years) 1,022,904 118,430 (11.6) 904,474 (88.4)
Sex, No. (%)
Male 4,443,260 396,760 (8.9) 4,046,500 (91.1)
Female 4,711,676 497,694 (10.6) 4,213,982 (89.4)
Setting, No. (%)
Urban 5,906,148 602,551 (10.2) 5,303,597 (89.8)
Rural 1,334,062 138,072 (10.3) 1,195,990 (89.7)
Missing 1,914,726 153,831 (8.0) 1,760,895 (92.0)
Townsend score, No. (%)
1 (least deprived) 1,887,796 215,341 (11.4) 1,672,455 (88.6)
2 1,687,078 175,969 (10.4) 1,511,109 (89.6)
3 1,771,062 172,697 (9.8) 1,598,365 (90.2)
4 1,745,740 159,622 (9.1) 1,586,118 (90.9)
5 (most deprived) 1,307,708 116,183 (8.9) 1,191,525(91.1)
Missing 755,552 54,642 (7.2) 700,910 (92.8)
Follow-up time
Mean years (SD) 7.6 (6.4) 10.7 (6.3) 7.3 (6.3)
https://doi.org/10.1371/journal.pone.0258219.t001
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In a validation analysis using NHANES, a US population-based survey, we found a
qualitatively similar trend in the sense that atopic dermatitis prevalence increased across
adulthood—4.5–20.7% reported symptoms in the past year among those ages 75 and older
Fig 2. Annual period prevalence of atopic dermatitis by participant characteristic and calendar period. Local
polynomial smoothed plots with shading indicating the 95% CIs generated from yearly cross-sectional calculations of
the proportion of participants with prevalent atopic dermatitis from ages 0 to 99.
https://doi.org/10.1371/journal.pone.0258219.g002
Table 2. Multivariable mixed effects logistic regression analysis of atopic dermatitis by age group, according to participant characteristic.
Variable Age Group
0–17 Years (N = 1,959,250) 18–74 Years (N = 5,603,315) 75–99 Years (N = 650,400)
AOR (95% CI) from regression model
Agea 0.86 (0.86, 0.86) 1.04 (1.03, 1.04) 1.06 (1.06, 1.06)
Calendar year at end of follow-upa 1.12 (1.11, 1.12) 3.46 (3.40, 3.52) 1.07 (1.07, 1.08)
Sex
Male Reference
Female 1.16 (1.14, 1.18) 2.72 (2.68, 2.76) 0.73 (0.70, 0.76)
Setting
Rural Reference
Urban 1.24 (1.21, 1.26) 1.13 (1.11, 1.15) 1.09 (1.06, 1.14)
Townsend score
Townsend 1 (least deprived) Reference
Townsend 2 0.94 (0.92, 0.96) 0.95 (0.94, 0.97) 0.92 (0.87, 0.97)
Townsend 3 0.90 (0.88, 0.92) 0.95 (0.93, 0.97) 0.84 (0.80, 0.89)
Townsend 4 0.85 (0.83, 0.87) 0.95 (0.93, 0.97) 0.87 (0.82, 0.92)
Townsend 5 (most deprived) 0.90 (0.88, 0.93) 1.02 (1.00, 1.05) 0.97 (0.91, 1.04)
Note. Each column represents a separate multivariable mixed effects logistic regression model. AOR = adjusted odds ratio.
a Modeled as a continuous variable, value represents adjusted odds of atopic dermatitis for each additional year of age or each additional calendar year, respectively.
https://doi.org/10.1371/journal.pone.0258219.t002
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(S2 Fig). Similar to our primary analysis, atopic dermatitis was also more common among
male older adults.
Atopic dermatitis activity
Atopic dermatitis activity was highest in older adults (59.7%, 95% CI 59.5–59.9%), followed by
children (48.4%, 95% CI 48.3–48.5%) then adults (42.2%, 95% CI 42.1–42.3%) (S3 Fig). The
results were similar after restricting to participants with at least 2 years of follow-up time in a
sensitivity analysis.
Atopic dermatitis severity
Across all ages, the majority of atopic dermatitis patients had mild disease (mean annual prev-
alence in children: 92.5%, adults: 77.1%, and older adults: 65.2%). The mean annual percentage
of atopic dermatitis patients with moderate and severe disease was highest among older adults
31.8% and 3.0%, respectively (Fig 3). By the end of follow-up, 46.2% of older adults met the
definition of moderate disease and 5.2% met the definition of severe disease. As described in
the methods, oral glucocorticoids were not included in the severity definition. The proportion
of individuals who received an oral glucocorticoid prescription (for any reason) was 8.7% of
those designated as having mild atopic dermatitis at the end of follow-up, 15.4% of those with
moderate atopic dermatitis, and 18.8% of those with severe atopic dermatitis.
Calendar trends
The total proportion of individuals with atopic dermatitis increased with calendar time (beta
from linear regression test for trend in the change in proportion per year = 0.005, p = 0.044,
S5 Table). In the most recent time span of 2008 to 2013, the increase in percent with atopic
Fig 3. Atopic dermatitis severity, by age group. Mean percentage of patients in each age group (children, adults, and older
adults) that meet the definition for mild, moderate, and severe atopic dermatitis. Bars indicate 95% confidence intervals.
https://doi.org/10.1371/journal.pone.0258219.g003
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dermatitis plateaued in children and adults but continued to rise in older adults (Fig 2). Addi-
tionally, in the mixed models, odds of atopic dermatitis increased with calendar time, and the
annual effect was strongest in adults ages 18–74 years (AOR 3.46, 95% CI 3.40–3.52) (Table 2).
Discussion
In a population-based cohort of over 9 million individuals from the UK, we found that the
prevalence of adult atopic dermatitis increased over time and with age. In comparison to chil-
dren ages 0–17 and adults ages 18–74, atopic dermatitis among older adults ages 75–99 years
was active for a greater proportion of the follow-up time, more likely to be moderate or severe,
and more likely to occur in men.
Although there are a few other studies that focus specifically on the epidemiology of atopic
dermatitis among older adults, review of additional population-based cohorts, including the
US NHANES validation cohort presented herein, the 2010 US National Health Interview Sur-
vey (NHIS) data [23], and two additional UK-based sources [24, 25] support our findings. The
period prevalence of self-reported atopic dermatitis in the 2010 NHIS was similar to our find-
ings: 9.0% among younger adults ages 18–32 and 11.4% among older adults ages 62–85. Our
findings are also consistent with published literature on calendar trends in children and youn-
ger adults: a systematic review and meta-analysis found there was a >10% increase in lifetime
prevalence of atopic dermatitis in the UK between 1990 and 2010 [26]. However, only one of
69 studies from this review included older adults from the time span of 2001–2005; our study
builds on this literature by including data on a large population of older adults over a 20-year
period.
Patient characteristics differed between age groups. For instance, similar to others, we
found that atopic dermatitis was more than twice as common among females compared to
males in the 18–74 age group [27–29]. However, our data suggest it is more common among
males compared to females in the 75–99 age group, which is consistent with data from studies
of smaller clinical population [30–32]. The reason for this is unclear; other authors have
hypothesized that higher average estradiol levels in older men compared to older women may
impact the production of cytokines that lead to the predominance of atopic dermatitis seen in
older adult males [7]. In terms of socioeconomic status (SES), similar to older reviews, our
study found a positive association of atopic dermatitis with less deprived or higher SES in chil-
dren, whereas in adults the association was less pronounced. A systematic review and meta-
analysis found that atopic dermatitis is more common among groups with higher SES, though
these were primarily studies of children [33]. More recent studies have found that this associa-
tion was strongest early in life, but that atopic dermatitis was more common among lower
socioeconomic groups in adulthood or did not vary by SES [5, 25, 34]. Additional study is war-
ranted to explore possible mechanisms for these findings. Finally, atopic dermatitis was more
common in urban areas at all ages, a finding that may relate to lifestyle or environmental char-
acteristics such as the types of microbes or increased pollution encountered in urban settings
[35, 36].
Limitations of our study include the possibility for misclassification bias, which may be
higher in adults than children, given a more heterogeneous presentation and a greater chance
for other common adult skin conditions to overlap with or be misdiagnosed as atopic dermati-
tis. We used a validated algorithm of physician diagnoses with good positive predictive value
for both children and adults in this cohort [9], and a previous study using this algorithm
showed similar prevalence curves even after adjusting for potential misdiagnosis of conditions
on the differential diagnosis of atopic dermatitis (e.g. psoriasis, contact dermatitis, scabies, seb-
orrheic dermatitis, and drug- or photo-induced dermatitis) [3]. Another limitation relates to
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the lack of detailed measures of disease activity, severity, and clinical presentation. We relied
on time-updated electronic medical record-based measures of disease activity and severity
because a large population-based cohort is needed to establish epidemiologic trends. While
more detailed data would be useful to additionally characterize atopic dermatitis among older
adults, it is likely to come from smaller and less representative populations. To address issues
with missing data, we performed multiple imputation in a random 1% sample of the popula-
tion and found the results consistent with those of complete case analysis in this sample.
Finally, although we had standardized data on participants ages 0–99, the mean duration of
follow-up was only 7.6 years, and as such we are unable to track an individual’s disease severity
and activity across the lifespan. Additional work is needed to further elucidate individual
changes in disease activity and severity across age groups.
Of note, in our validation analysis using NHANES data, the trend of increasing prevalence
among older adults was sensitive to the specific question used–the prevalence did not increase
among those also reporting flexural rashes and physician diagnosis. This could be because
these questions were designed to detect atopic dermatitis in children and younger adults, who
more commonly present with flexural disease and may be more likely to be recognized and
diagnosed by physicians [6, 7]. Future research should examine the validity of diagnostic crite-
ria among older adults and regional variations in physician diagnosis and terminology.
There are a number of reasons why additional study of atopic dermatitis among older
adults is important. First, older adults are the most rapidly increasing demographic segment
[8], and atopic dermatitis appears to be increasing among this group. Second, older adults are
at greater risk for a number of comorbid conditions that may be more common among indi-
viduals with atopic dermatitis, including depression and anxiety, cardiovascular disease, osteo-
porosis, and dementia [37–39]. Third, the clinical presentation and underlying pathogenesis
may differ among this age group. Previous studies have found that atopic dermatitis presents
in a different distribution on the body in older adults—instead of the classic flexural lichenifi-
cation found in children and younger adults, atopic dermatitis in older adults more often has
reverse signs of lichenification around unaffected elbow and knee folds and higher incidence
on the buttocks and genitals instead of on the face and scalp [7, 40]. Moreover, older adults
may have other common pruritic skin conditions that must be ruled out prior to the diagnosis
of atopic dermatitis. Additionally, they may also have other coexisting health conditions and
are more likely to take systemic medications that may cause pruritus and rash that could be
mistaken for atopic dermatitis [7]. Additional research is needed to refine diagnostic criteria,
assess detailed clinical characteristics, ascertain the inflammatory profile and biomarkers in
this population, and identify disease triggers. Finally, this population is less likely to be repre-
sented in clinical trials [41], and should be considered for inclusion in testing new small mole-
cules and biologic agents for atopic dermatitis.
Supporting information
S1 Fig. Correcting for ascertainment bias. Local polynomial smoothed plots with shading
indicating the 95% CIs generated from yearly cross-sectional calculations of the prevalence of
atopic dermatitis from ages 0 to 99 within a 1% random sample of the population. In a correc-
tion for ascertainment bias, the prevalence of atopic dermatitis by year of age was restricted to
those who had at least one medical code corresponding to a physician’s visit during that year.
(PDF)
S2 Fig. Prevalence of atopic dermatitis across age in the 2005–2006 NHANES. Local poly-
nomial smoothed plots with shading indicating the 95% CIs generated from yearly cross-sec-
tional calculations of the percent with prevalent atopic dermatitis during the past year from
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ages 0 to 85+. A) Three definitions representing prevalence of atopic dermatitis were formed
by separate combinations of survey questions relevant to atopic dermatitis B) Prevalence of
atopic dermatitis by sex using Definition 1 and C) Prevalence of atopic dermatitis by income
using Poverty Income Ratio (PIR) using Definition 1.
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S3 Fig. Atopic dermatitis activity, by age group. Mean proportion of years with prevalent
atopic dermatitis as a percent of total years of follow-up 95% confidence interval by age group.
Primary analysis includes atopic dermatitis activity regardless of the number of years of fol-
low-up. Sensitivity analysis excludes those with less than 2 years of follow-up time (total of
2.3% of individuals across all age groups).
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S2 Table. Proportion of missing data for setting by age group.
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S3 Table. Proportion of missing data for Townsend score by age group.
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S4 Table. Mixed effects logistic regression results for complete case analysis and multiple
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S5 Table. Mean percent of atopic dermatitis across age groups by 5-year time spans from
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